Page last updated: 2024-10-25

ciglitazone and Hyperhomocysteinemia

ciglitazone has been researched along with Hyperhomocysteinemia in 2 studies

ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.

Hyperhomocysteinemia: Condition in which the plasma levels of homocysteine and related metabolites are elevated (

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Mishra, PK1
Tyagi, N1
Sen, U1
Joshua, IG2
Tyagi, SC2
Reddy, HK1
Koshy, SK1
Wasson, S1
Quan, EE1
Pagni, S1
Roberts, AM1

Other Studies

2 other studies available for ciglitazone and Hyperhomocysteinemia

ArticleYear
Synergism in hyperhomocysteinemia and diabetes: role of PPAR gamma and tempol.
    Cardiovascular diabetology, 2010, Sep-09, Volume: 9

    Topics: Animals; Antioxidants; Cardiomyopathies; Cyclic N-Oxides; Diabetes Complications; Diabetes Mellitus,

2010
Adaptive-outward and maladaptive-inward arterial remodeling measured by intravascular ultrasound in hyperhomocysteinemia and diabetes.
    Journal of cardiovascular pharmacology and therapeutics, 2006, Volume: 11, Issue:1

    Topics: Animals; Collagen; Coronary Artery Disease; Coronary Vessels; Diabetes Complications; Diabetes Melli

2006